December 17, 2024 ‐ Psychiatrist.com
By Afamefuna Onyeogulu
Executives at Reunion Neuroscience sat down with Psychiatrist.com recently to discuss the importance of maternal health, postpartum depression and their groundbreaking new initiative: RE104. President and CEO Greg Mayes and Chief Science Officer Nate Bryson talked about this novel drug that has the potential to transform maternal mental health.
November 18, 2024 ‐ Carta.com
By Kiley Roache
The CEO of Reunion Neuroscience, a company developing a drug to treat postpartum depression and mental health distress related to cancer, took a unique approach to advance company goals. Reunion was formerly a public company, but after current CEO Greg Mayes took over, the company went private and raised a $103 million Series A financing, which it announced in May of this year.
November 7, 2024 ‐ PSQH
By Sheryl Kingsberg, PhD
Postpartum depression (PPD) is a potentially serious mood disorder that affects approximately one in seven women within the first year after giving birth. As with general depression, the combination of symptoms can be debilitating and even fatal: PPD has been shown to raise the risk of maternal suicide, along with comorbidities including diabetes, hypertension, hyperlipidemia and stroke. The emotional and physical devastation can ripple through a woman’s life, disrupting careers, relationships and family life.
October 16, 2024
By Kevin Kunzmann
Investigators including Sheryl Kingsberg, PhD, chief of the division of behavioral medicine, department of OB/GYN, University Hospitals Cleveland Medical Center, are assessing it in RECONNECT for outcomes including change in total 10-item Montgomery-Åsberg Depression Rating Scale (MADRS) score from baseline to day 7 in treated patients versus control; change in total MADRS score from baseline to days 1, 14, and 28, as well as rate of patients with ≥50% reduction in depressive symptoms per MADRS; and rate of patients to achieve remission (MADRS scores of ≤10). Safety and tolerability outcomes will additionally be assessed through the trial.
October 16, 2024
By Kevin Kunzmann
Reunion Neuroscience recently announced the launch of the phase 2 RECONNECT study, a multicenter, randomized, double-blind, parallel-group clinical trial assessing the efficacy and safety of subcutaneous 30 mg RE104 versus an active dose control (1.5 mg) in adult female patients with moderate to severe PPD. As of late July, the first patient had already been dosed, with plans to conclude the trial by June 2025.